Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
Portfolio Pulse from Benzinga Insights
In the last three months, 7 analysts have provided ratings for Ovid Therapeutics (NASDAQ: OVID), with 6 being bullish and 1 indifferent. The average 12-month price target has decreased by 48.9% to $3.03. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Ovid Therapeutics has shown strong financial performance with significant revenue growth, high net margin, and efficient use of assets.
August 19, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ovid Therapeutics has received 7 analyst ratings in the last three months, with 6 being bullish. The average 12-month price target has decreased by 48.9% to $3.03. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Ovid has shown strong financial performance with significant revenue growth, high net margin, and efficient use of assets.
The majority of analysts are bullish on Ovid Therapeutics, indicating positive sentiment. Despite the decrease in the average price target, the company's strong financial performance, including significant revenue growth and high net margin, suggests a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100